Portfolio company
Cytoki Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops interleukin-22 based therapeutics for patients with obesity, type 2 diabetes and inflammatory bowel disease.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Antag Therapeutics
This company develops GIP receptor antagonist therapies to treat patients living with obesity, type 2 diabetes and metabolic disorders.
Synthekine
This company develops engineered cytokine therapeutics and protein engineering platforms for patients with cancer and autoimmune or inflammatory diseases.
GutCRINE
This company develops microbiome-derived pharmabiotics to treat metabolic and age-related disorders including obesity and type-2 diabetes for patients with chronic diseases.
AdipoPharma
This clinical-stage biotechnology company develops therapeutic peptides to treat insulin resistance and type 2 diabetes for patients with metabolic disorders.
Enthera Pharmaceuticals
This biotech company develops monoclonal antibodies and fusion proteins for patients with autoimmune conditions including type 1 diabetes and inflammatory bowel disease.
AdipoPharma SAS
This biotech company develops a therapeutic peptide to treat insulin resistance and type 2 diabetes for patients with metabolic diseases.
Calyx Therapeutics
This company develops oral therapies for diabetes and inflammatory diseases using natural plant extracts for pharmaceutical and biotechnology organisations.
Sitryx Therapeutics
The company develops oral small molecule therapies to treat patients with autoimmune and inflammatory diseases by regulating immune cell metabolism.